Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVORMeletios Α. Dimopoulos, Rubén Niesvizky, Karim Iskander et al.|Blood|2018Cited by 44
Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor StudyMeletios Α. Dimopoulos, Rubén Niesvizky, David S. Siegel et al.|Blood|2017Cited by 2